中国大陆腹主动脉瘤的血管内修复:系统综述与Meta分析
本系统综述与Meta分析纳入16项中国研究、共3024例腹主动脉瘤患者,评估血管内动脉瘤修复(EVAR)的安全性与结局。汇总技术成功率为95%(95%CI 92-96%),内漏率7%(95%CI 6-8%),30天死亡率为2%(95%CI 1-3%)。作者认为EVAR在中国大陆患者中取得令人鼓舞的中期结局,长期结局需未来研究检验。
要点
- 汇总技术成功率为95%(95%CI 92-96%),内漏率为7%(95%CI 6-8%)。
- 30天死亡率为2%(95%CI 1-3%),随访死亡率为5%(95%CI 3-8%)。
- 作者认为EVAR在中国大陆患者中取得令人鼓舞的中期结局,长期结局需未来研究检验。
核心结论
- 作者认为EVAR技术治疗中国大陆腹主动脉瘤患者取得令人鼓舞的中期结局,长期结局需未来研究检验。
研究设计与样本
- 系统检索PubMed、Embase、中国国家知识基础设施和中国生物医学数据库,纳入2000年1月至2020年12月发表的英文中国研究。
- 由两名独立观察者筛选文献、评估方法学质量并提取数据,纳入研究报道EVAR的临床结局和术后并发症。
- 共纳入16项研究,合计3024例腹主动脉瘤患者。
主要发现
- 随访时间范围为1至133个月,平均随访时间38.5个月,平均年龄69.2岁,平均动脉瘤直径56.1毫米。
- 汇总技术成功率为95%(95%CI 92-96%),内漏率为7%(95%CI 6-8%)。
- 需要再干预的内漏率为3%(95%CI 3-4%)。
- 30天并发症发生率为9%(95%CI 6-14%),30天死亡率为2%(95%CI 1-3%)。
- 随访死亡率为5%(95%CI 3-8%)。
关键数值与推荐
- 汇总技术成功率为95%(95%CI 92-96%)。
- 内漏率为7%(95%CI 6-8%),需要再干预的内漏率为3%(95%CI 3-4%)。
- 30天并发症发生率为9%(95%CI 6-14%),30天死亡率为2%(95%CI 1-3%)。
- 随访死亡率为5%(95%CI 3-8%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this study was to evaluate the safety, applicability, and outcomes of the endovascular aneurysm repair (EVAR) technique for patients in mainland China with abdominal aortic aneurysm (AAA) by performing a systematic review. METHODS: We conducted a systematic search using the PubMed, Embase, Chinese National Knowledge Infrastructure, and Chinese Biomedical databases to identify Chinese studies on the management of AAAs using the EVAR technique published in English between January 2000 and December 2020. Two independent observers selected studies for inclusion in the study, assessed the methodological quality of the included studies, and extracted the data. The included studies investigated the clinical outcomes and postprocedural complications of using EVAR techniques. RESULTS: Sixteen studies reported a total of 3,024 AAA patients. The follow-up period ranged from 1 to 133 months. The mean follow-up time was 38.5 months, the mean age was 69.2 years, and the mean aneurysm diameter was 56.1 mm. The pooled technical success rate was 95% (95% confidence interval [CI]: 92-96%). The endoleak rate was 7% (95% CI: 6-8%). The rate of endoleak requiring reintervention was 3% (95% CI: 3-4%). The 30-day morbidity rate was 9% (95% CI: 6-14%). The 30-day mortality rate was 2% (95% CI: 1-3%). The follow-up mortality was 5% (95% CI: 3-8%). CONCLUSIONS: The results of the study showed that using the EVAR technique for treating patients in mainland China with AAAs produced encouraging mid-term outcomes. Long-term outcomes should be examined in future research.
引用
- Li Y, He C, Zhang H, et al. Endovascular Repair for Abdominal Aortic Aneurysm in Mainland China: A Systematic Review and Meta-Analysis. Ann Vasc Surg. 2022. PMID: 36343863. doi:10.1016/j.avsg.2022.09.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。